Teachers Advisors’s Filana Therapeutics FLNA Stock Holding History

Teachers Advisors’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-7,533	Closed	-$100K	–	3115
2015 Q1	$100K	Hold	7,533	–	–	﹤0.01%	3026
2014 Q4	$107K	Hold	7,533	–	–	﹤0.01%	3031
2014 Q3	$206K	Hold	7,533	–	–	﹤0.01%	2868
2014 Q2	$303K	Buy	+7,533	New	+$279K	﹤0.01%	2734

Other funds holding FLNA

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Teachers Advisors's FLNA Position: Q2 2015 in Review

Teachers Advisors sold out of Filana Therapeutics (FLNA) in Q2 2015, closing a stake of 7,533 shares — an estimated $100K sold.

Teachers Advisors first reported a position in FLNA in Q2 2014 and held it in 4 quarters. The position peaked at $303K in Q2 2014. 66 funds tracked by Wall St. Rank hold FLNA as of Q2 2015.

Teachers Advisors reported no remaining Filana Therapeutics position as of Q2 2015 after selling out during the quarter.
Teachers Advisors sold 7,533 Filana Therapeutics shares in Q2 2015, an estimated $100K.
Teachers Advisors first reported a position in Filana Therapeutics in Q2 2014 and held it in 4 quarters.
Teachers Advisors's Filana Therapeutics position peaked at $303K in Q2 2014.
66 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2015.

Based on Teachers Advisors's 13F filing for Q2 2015, filed 10 Aug 2015.